TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05294341
Drug: Norethindrone Acetate 5 MG
Normalized name: norethindrone acetate 5 MG
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As specified in arm design
Study: NCT01201278
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
Study: NCT01201278
Drug: Insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
Study: NCT01201278
Drug: Insulin LISPRO
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous insulin lispro 8 U
Study: NCT04702997
Drug: Bardoxolone methyl oral capsule
Normalized name: methylal
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bardoxolone methyl capsules dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status
Study: NCT06062953
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50-150 mg flexible dosing before bed time
Study: NCT04573686
Drug: Erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin will be given subcutenous to all patients
Study: NCT04675931
Drug: IV Artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Parenteral artesunate is the WHO recommended first line treatment for severe malaria. Hence IV artesunate is used as comparator. Also, this will be used as rescue medication for participants where IV KAE609 is not working.
Study: NCT04675931
Drug: Coartem
Normalized name: Coartem
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Standard of Care
Study: NCT05500261
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intranasal administration of dexmedetomidine
Study: NCT04955886
Drug: Surufatinib(HMPL-012)
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib(250mg) will be orally administered within 1 hour after breakfast once a day (QD) , Toripalimab was administered intravenously at a fixed dose of 240 mg, and the infusion time was 60 ± 5 min, once every 21 days. The cumulative longest medication period is 2 years. Until disease progression, death, intolerable toxicity or other protocol specified end-of-treatment criteria is met .
Study: NCT04047355
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol is a beta-blocker used to treat high blood pressure, irregular heartbeats, and tremors. It is used after a heart attack and to prevent migraine headaches and chest pain. It is also used off-label for anxiety and PTSD.
Study: NCT04722471
Drug: Vaginally administered progesterone
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The artificial endometrial preparation for an embryo transfer with the use of 400 mg vaginal tablet (one tablet twice a day) or 200 mg (two tablets twice a day)
Study: NCT06361576
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: As per product label
Study: NCT05476770
Drug: Tagraxofusp
Normalized name: Tagraxofusp
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dose will be assigned at study entry. Give IV over 15 minutes.
Study: NCT05476770
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/m\^2 will be given IV over 30 minutes on days 1-5.~Infusion will start 30 minutes after start of tagraxofusp on days 4 and 5.
Study: NCT05476770
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2000 mg/m2 intravenously will be given daily over 1-3 hours for 5 days on days 1 through 5. Infusion will begin 4 hours after start of fludarabine. Because of an increased risk of neurotoxicity, it is recommended that IT cytarabine be separated from high dose IV cytarabine administration by at least 24 hours on C1D1.
Study: NCT05476770
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * 20 mg/m2/day divided BID (max 40 mg/day) given orally on days 1 through 5 and 15 through 19. The two doses should be separated by at least 8 hours.~* Any oral formulation of dexamethasone is acceptable.~* IV may be given if oral formulation is not tolerated
Study: NCT05476770
Drug: Vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * 1.5 mg/m2 (maximum dose 2 mg) given intravenously as an IV push over 1-5 minutes or infusion via minibag as per institutional policy on days 1, 8, 15, and 22.~* Infusion will start 30 minutes after start of tagraxofusp on day 8.
Study: NCT05476770
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * 75 mg/m2 subcutaneously or intravenously will be given daily over 15 minutes for 5 days on days 1 through 5.~* Azacitidine will be given 30-60 minutes before beginning the tagraxofusp infusion.
Study: NCT05476770
Drug: Cytarabine IT
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Give intrathecally:~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients ≥3 years of age~If given as part of Triple IT Therapy:~AML Patients:~Age 1-1.99 - 24 mg Age 2-2.99 - 30 mg Age ≥3 years of age - 36 mg~AML Patients:~Age 1-1.99 - 16 mg Age 2-2.99 - 20 mg Age 3-8.99 - 24 mg Age ≥9 years of age - 30 mg
Study: NCT05441410
Drug: Pyronaridine Tetraphosphate, Artesunate Drug Combination
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Combination drug for treatment of uncomplicated malaria
Study: NCT05525780
Drug: GB-5001
Normalized name: GB-13
DrugBank: GB-13 (DB18387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depending on the cohort, volume will be varied to administer.
Study: NCT05772234
Drug: Lactated ringers solution
Normalized name: potassium chloride 20 MEQ/L in lactated Ringers solution with dextrose 5 % Injectable Solution
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous 20 mL/kg Ringer's lactate solution within 60 min from the start of ESWL, directly followed by 3 mL/kg per h for 8 h.
Study: NCT00194961
Drug: Recombinant Human Growth Hormone
Normalized name: Recombinant human growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05848102
Drug: dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FORXIGA（Dapagliflozin Tablets), manufacturer/marketer: AstraZeneca, salt composition: Dapagliflozin (10mg), one tablet once and once a day.
Study: NCT05924373
Drug: Human Dental Fulp Stem Cells
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drugs: Based on the initial periodontal treatment (supragingival cleansing, subgingival scaling and root planning), human pulp stem cell injections will be given for a single or two local injection
Study: NCT06426511
Drug: Toripalimab+Chemotherapy
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment. Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians.
Study: NCT06426511
Drug: Toripalimab+Chemotherapy followed by consolidation toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After surgical resection, patients received 4 cycle of toripalimab (240 mg) in combination with platinum-based adjuvant treatment, and then maintenance treatment with single-agent toripalimab (240 mg) once every 3 weeks for up to 13 cycles.~Administration of standard postoperative adjuvant chemotherapy for stage IB disease was not mandatory; decisions about whether patients with IB disease would receive adjuvant chemotherapy were made by the physicians.
Study: NCT05486819
Drug: Propofol Injection
Normalized name: propofol Injection
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: adding lignocaine or sodium bicarbonate to propofol to reduce pain during injection
Study: NCT06585163
Drug: Hydrocodone Bitartrate
Normalized name: Hydrocodone Bitartrate
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone bitartrate oral suspension
Study: NCT06585163
Drug: Doxapram Hydrochloride
Normalized name: Doxapram Hydrochloride
DrugBank: Doxapram (DB00561)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxapram hydrocholoride oral suspension
Study: NCT05693428
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 5-6 mg/kg/h intravenously on a perfusor.
Study: NCT05693428
Drug: Isoflurane
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: isoflurane was used as anaesthetice of - 1.1-1.2 MAC.
Study: NCT05693428
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sevoflurane was used as an anaesthetic in a dose of - 1.7-1.9 MAC
Study: NCT05324748
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection with prednisolon
Study: NCT05324748
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0,9%
Study: NCT04912726
Drug: Sildenafil Injectable Product
Normalized name: sildenafil Injectable Product
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention group will receive intravenous sildenafil loading dose of 0.4 mg / kg in 3 hours and continue in continuous infusion at 1.6 mg / kg / day (0.067 mg / kg / h).
Study: NCT04728893
Drug: Nemtabrutinib
Normalized name: Nemtabrutinib
DrugBank: Nemtabrutinib (DB18866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nemtabrutinib tablets administered PO QD.
Study: NCT05249426
Drug: BI 765063
Normalized name: BI-765063
DrugBank: BI-765063 (DB17482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))
Study: NCT05249426
Drug: Ezabenlimab
Normalized name: Ezabenlimab
DrugBank: Ezabenlimab (DB17483)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))
Study: NCT05249426
Drug: BI 836880
Normalized name: BI-836880
DrugBank: BI-836880 (DB17484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 836880 (anti-Vascular Endothelial Growth Factor (VEGF) / Angiopoetin 2 (Ang2))
Study: NCT05249426
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab
Study: NCT06461949
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dupilumab (Dupixent) is a human monoclonal antibody administered via subcutaneous injection to treat various conditions such as Chronic Rhinosinusitis with Nasal Polyps, Asthma and Eosinophilic Esophagitis.
Study: NCT05209256
Drug: Alflutinib plus chemotherapy
Normalized name: Alflutinib
DrugBank: Alflutinib (DB16087)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Those in the combination group received concurrent alflutinib (80 mg daily), as well as carboplatin (area under the curve \[AUC\] of 5 on day 1) and pemetrexed (500 mg/m2 on day 1) in a 3-week cycle for up to four cycles, followed by maintenance on alflutinib and pemetrexed until disease progression, unacceptable toxicity, or death.
Study: NCT06092684
Drug: BT-KTM-I
Normalized name: iobenguane I-131
DrugBank: Iobenguane (DB06704)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dosage for anesthesia induction period was 0.5mg/kg, and the dosage for anesthesia maintenance period was 0.5mg/kg/h.
Study: NCT05272202
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: STIM-MOTANA is an interventional and prospective study conducted in patients scheduled for surgery under general anesthesia, involving EEG measurements and median nerve stimulation. In this study, 30 patients will undergo surgery under total intravenous anesthesia using a propofol target-controlled infusion pump. The rest of the anesthetic protocol will be at the discretion of the anesthesiologist in charge. After surgery, patients will have a gradual decrease of propofol at different effect-site concentrations (from 4.0 μg/ml to 2.0 μg/ml, in increments of 0.5 μg/ml).
Study: NCT04373564
Drug: Gadoxetate disodium
Normalized name: Gadoxetate Disodium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as defined by the treating physician as part of routine clinical practice
Study: NCT04373564
Drug: Gadobenate dimeglumine
Normalized name: Gadobenate Dimeglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as defined by the treating physician as part of routine clinical practice
Study: NCT04373564
Drug: Gadodiamide
Normalized name: Gadodiamide
DrugBank: Gadodiamide (DB00225)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as defined by the treating physician as part of routine clinical practice
Study: NCT04373564
Drug: Gadoterate meglumine
Normalized name: Gadoterate meglumine
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as defined by the treating physician as part of routine clinical practice
Study: NCT04373564
Drug: Gadobutrol
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as defined by the treating physician as part of routine clinical practice
Study: NCT06106308
Drug: Onvansertib
Normalized name: Onvansertib
DrugBank: Onvansertib (DB15110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsule
Study: NCT06106308
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV Infusion
Study: NCT05183802
Drug: Setmelanotide, administered subcutaneously [SC], once daily.
DrugBank: Setmelanotide (DB11700)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dosing based on age, and titrated from starting dose to target dose.
Study: NCT04373564
Drug: Gadoteridol
Normalized name: Gadoteridol
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as defined by the treating physician as part of routine clinical practice
Study: NCT05828069
Drug: Tovorafenib
Normalized name: Tovorafenib
DrugBank: Tovorafenib (DB15266)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06156566
Drug: Tecovirimat Oral Capsule
Normalized name: tecovirimat Oral Capsule
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 600 mg, twice daily, 14 days.
Study: NCT06719557
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution
Study: NCT06720337
Drug: bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive 18 ml 0.5% bupivacaine (Sunnypivacaine®) using Ultrasound-Guided TAP Block Technique
Study: NCT06720337
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive plus 0.5 µg/kg of dexmedetomidine (Precedex® 100 µg/ml) diluted in 2 ml of normal saline at each side
Study: NCT06720337
Drug: MgSO4
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will receive plus 1.5 mL (150 mg) MgSO4 and 0.5 mL normal saline at each side
Study: NCT06297499
Drug: Ondansetron 8mg
Normalized name: ONDANSETRON 8MG ORAL DISINTEGRATING TAB
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administration of an IV solution of 8mg ondansetron (4ml)
Study: NCT05642026
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this group will receive CINB (continuous local intercostal infusion of 0.2% Ropivacaine). A single catheter will be placed for short segment involvement and two catheters will be placed in series for longer segments of involvement. If necessary and as part of standard of care, CINB treatment will continue after patient discharge. The administration of CINB therapy will continue in the same manner as inpatient therapy.
Study: NCT06066710
Drug: Propranolol
Normalized name: Propranolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol will be given on a titration schedule in which participants will begin with small doses of the drug and increase to a larger dosage over the course of three weeks. Propranolol will be taken for a total of 9 weeks.
Study: NCT05262166
Drug: INTRATHECAL dexmedetomidine INJECTION
Normalized name: dexmedetomidine Injection
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: intrathecal bolus of 3ml bupivacaine 0.5% (15mg) plus 10 micrograms dexmedetomidine at 2-3 or 3-4 spinal level.
Study: NCT06470347
Drug: A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: During treatment, subjects were given 400 mg pyrrotinib once daily, within 30 minutes after breakfast.
Study: NCT05646602
Drug: Collagenase Clostridium Histolyticum
Normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralesional injection
Study: NCT05461092
Drug: Thoracolumbar Interfascial Plane (TLIP) Block of bupivacaine
Normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient receives standard of care anesthesia with TLIP Block of bupivicaine (local anesthetic) intraoperatively after anesthesia administration and before spinal fusion.
Study: NCT06399718
Drug: BOTOX
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intramuscular Injections
Study: NCT04904302
Drug: Sitravatinib
Normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06547775
Drug: KN069
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution for SC injection
Study: NCT06585059
Drug: TQB2928 injection + Almonertinib Mesilate Tablets
Normalized name: phentolamine mesylate Injection
DrugBank: Almonertinib (DB16640)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2928 is a recombinant fully humanized Immunoglobulin G4 (IgG4) monoclonal antibody that can promote tumor cell phagocytosis by macrophages and exert anti-tumor effects.~Almonertinib Mesilate Tablets is a third generation of EGFR-TKI targeting drug.
Study: NCT04566120
Drug: cinnamon extract mouthwash
Normalized name: cinnamon allergenic extract
DrugBank: Cinnamon (DB10520)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cinnamon extract mouthwash
Study: NCT04566120
Drug: chlorohexidine based mouthwash
Normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chlorohexidine based mouthwash
Study: NCT06375317
Drug: PD-L1 inhibitor: Adebrelimab Injection；Regorafenib Tablets
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PD-L1 injection: 20 mg/kg, administered every 3 weeks (Q3W).~Regorafenib: 80 mg, orally, once daily (qd), continuously for 14 days per cycle, followed by a 7-day rest period, administered every 3 weeks (Q3W).~FOLFOX regimen: Oxaliplatin 85 mg/m2, Calcium folinate 400 mg/m2, Fluorouracil 400 mg/m2 as an IV bolus, followed by Fluorouracil 1200 mg/m2 infusion over 23 hours, administered every 3 weeks (Q3W) for a total of 6 cycles.~The above doses are recommended doses.
Study: NCT04748848
Drug: CC-90011
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle. The dose escalation is designed to explore three dose levels of CC-90011, for example 20, 40, and 60 mg as determined by Bayesian design.
Study: NCT04748848
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle with a brief dose ramp-up for Cycle 1 with the dosing of 100 mg on Day 1, 200 mg on Day 2, and 400 mg on Day 3. Venetoclax should be administered at 400 mg on subsequent days.
Study: NCT04748848
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine is administered on Days 1 to 7 of each 28-day cycle as an IV infusion or SC injection at 75 mg/m2
Study: NCT04748848
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax is administered orally QD on Days 1 to 28 of each 28-day cycle
Study: NCT05322447
Drug: L-Carnitine ( high dose)
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: will receive a high dose of L- Carnitine 18 gm/day as a continuous intravenous infusion to reach double the normal plasma level
Study: NCT04748848
Drug: CC-90011
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-90011 will be given PO on Days 1, 8, and 15 of continuous 4-week (28-day) cycle at the recommended phase to dose of CC-90011 confirmed in dose escalation.
Study: NCT06106776
Drug: Chimeric Antigen Receptor
Normalized name: Chimeric antigen receptor
DrugBank: B7-H3-specific chimeric antigen receptor T cells (DB18567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will evaluate the incidence of cardiac dysfunction at 7 days and 1 month after chimeric antigen receptor-T cell infusion (tisagenlecleucel, axicabtagene ciloleucel e brexucabtagene autoleucel).